<?xml version="1.0" encoding="UTF-8"?>
<p id="par0165">Kenichi et al reported new non-peptide SARS-CoV 3CL
 <sup>pro</sup> inhibitors 
 <xref rid="bib0585" ref-type="bibr">[117]</xref> by introducing decahydroisoquinoline at the S2 position by connecting the cyclohexyl group of the substrate-based inhibitor 
 <bold>75</bold> (
 <xref rid="fig0055" ref-type="fig">Fig. 11</xref> ) 
 <xref rid="bib0590" ref-type="bibr">[118]</xref>. The resulting compounds (
 <bold>76</bold>-
 <bold>80,</bold>
 <xref rid="fig0055" ref-type="fig">Fig. 11</xref>) showed moderate but very promising inhibitory activities against SARS-CoV 3CL
 <sup>pro</sup>, which suggested that the decahydroisoquinoline scaffold could be a novel scaffold at the S2 position for SARS-CoV 3CL
 <sup>pro</sup> inhibition.
</p>
